May 16, 2013—The long-awaited regulation to implement health care reform’s partial limit on 340B discounts for orphan drugs is back on hold.
On May 8, the White House Office of Management and Budget (OMB) reported online that its review of the Health Resources and Services Administration’s (HRSA) proposed 340B orphan drug exclusion final rule had been extended.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)